An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer
Michael H. Brave(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research), Daniel L. Suzman(United States Food and Drug Administration), Joyce Cheng(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Jamie R. Brewer(Center for Democracy in the Americas), Chana Weinstock(United States Food and Drug Administration), Dow-Chung Chi(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Lijun Zhang(Dalian Medical University), Amna Ibrahim(Beni-Suef University)
Cited by 29
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k